ABcann Extends Agreement With Medical Cannabis Pioneer
09 May 2017 - 9:30PM
ABcann Global Corporation (TSX-V:ABCN) (the “Company”) is pleased
to announce that Raphael Mechoulam has agreed to extend his
role as an advisor to the Company.
Mechoulam is an Israeli Organic Chemist, and a
professor at the Hebrew University of Jerusalem’s Medical
Faculty, Institute for Drug Research. Professor Mechoulam has been
nominated for the Nobel Prize, and is often regarded as the "Father
of Marijuana Research."
Professor Mechoulam has been a pioneer in medicinal
cannabis research for more than five decades. His most significant
cannabis research accomplishments include determining the chemical
structure of cannabidiol (CBD) in 1963 which led to isolating and
synthesizing tetrahydrocannabinol (THC) in 1964 and isolating and
elucidating the structure of the brain's first endogenous
cannabinoid, Anandamide, in 1992.
“Professor Mechoulam’s experience in medicinal
cannabis is an invaluable resource for ABcann as we enter the most
aggressive growth stage in the company’s history. The Company has
invested heavily to build and extend its early leadership in
advanced pharmaceutical-grade cannabis production. Professor
Mechoulam’s advice, guidance, and unmatched expertise in the field
has played a major role in achieving this, says Aaron Keay CEO and
Director of ABcann.
“I have followed the development of cannabis for
medical use for many years. There is no doubt that it is very
helpful in numerous diseases, however many physicians refrain from
prescribing it. I believe that the route followed by ABcann for
standardized cannabis grown under strict conditions, leading to
reproducible contents, will not only satisfy physicians but will
also make possible clinical trials which will develop the evidence
to transform how cannabis is perceived by the pharmaceutical
industry and the regulatory agencies” said Professor Mechoulam.
“The Professor’s agreement to extend his
relationship with ABcann is one of the strongest votes of
confidence our company could ever receive,” says Ken Clement,
Founder and Executive Chairman of ABcann.
ON BEHALF OF THE BOARD OF DIRECTORS OF
ABCANN GLOBAL CORPORATION
“Aaron Keay”
Aaron Keay Director
For further information, please contact Aaron Keay
by phone at (604) 323-6911 or by email at
aaron@abcannglobal.com OR Leo Karabelas by phone (416)
543-3120 or by email at leo.k@abcannglobal.com.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Disclaimer for Forward-Looking
Information
Certain statements in this release are
forward-looking statements, which reflect the expectations of
management regarding the proposed Qualifying Transaction, the
Concurrent Financings and ABcann’s future business plans.
Forward-looking statements consist of statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to: the terms of the Transaction; the terms of the Concurrent
Financings and the use of proceeds thereof; the consistency of
ABcann’s product; and ABcann’s future site development and
expansion plans. Such statements are subject to risks and
uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
statements, including that: the TSXV may not approve the
Transaction; the Transaction may not be completed for any other
reason; the Concurrent Financings may not be completed on the terms
contemplated or at all; the proceeds of the Concurrent Financings
may not be allocated as currently contemplated; or factors may
occur which cause ABcann’s currently contemplated expansion and
development plans to cease or otherwise change. No assurance can be
given that any of the events anticipated by the forward-looking
statements will occur or, if they do occur, what benefits the
Company or the Resulting Issuer will obtain from them. Readers are
urged to consider these factors carefully in evaluating the
forward-looking statements contained in this news release and are
cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by these
cautionary statements. These forward-looking statements are made as
of the date hereof and the Company disclaims any intent or
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or results or
otherwise, except as required by applicable securities laws.
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jul 2023 to Jul 2024